Treatment-free remission seems to be achievable in patients with chronic myeloid leukemia (CML) who have achieved sustained deep molecular response (DMR) after discontinuation of second-line nilotinib therapy. Results from ...
Feb 19, 2018
0
7
New evidence suggests that using advanced genetics technologies to monitor for remaining cancer cells after treatment may soon become an effective tool to inform treatment decisions and ultimately predict patient outcomes ...
Jul 9, 2013
0
0
Singaporean researchers have developed a genetic test that can reliably identify different subtypes of a specific kind of kidney cancer. The test has the potential to improve treatment, as it can assess a patient's prognosis ...
Jan 14, 2015
0
19
(HealthDay)—For patients with chronic myeloid leukemia (CML), tyrosine kinase inhibitor (TKI) therapy can be safely discontinued and yields high rates of treatment-free remission (TFR), according to a study published online ...
Apr 16, 2019
0
1
Two oral targeted drugs approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability, according to results of a large international clinical trial led by researchers at Dana-Farber Cancer ...
Aug 21, 2013
0
0
The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based ...
Sep 27, 2014
0
0
In a recent study published in Leukemia, Finnish researchers investigated why some patients with chronic myeloid leukemia (CML) can discontinue their daily medication safely.
Nov 6, 2023
0
0
Markers such as CA9, CD31, CD34 and VEGFR1/2 in the primary tumours might serve as predictors of a good response to a sunitinib treatment in patients with metastatic clear cell renal cell carcinoma (ccRCC), according to a ...
Mar 18, 2013
0
0
Among patients with previously treated HER2-positive metastatic breast cancer, those who received pyrotinib plus capecitabine had longer overall survival than those who received lapatinib (Tykerb) plus capecitabine, according ...
Dec 8, 2021
0
2
There are more than 100 mutations of the protein behind the deadly brain cancer, glioblastoma, however an international research team has discovered something these mutations have in common. The new understanding could lead ...
Apr 30, 2019
0
1
